Table 8 Outcomes of the scenario analyses
Description | Incremental costs (discounted) | Incremental QALYs (discounted) | ICER (discounted) |
|---|---|---|---|
Base case | − €6136 | 0.20 | Dominant |
The discount rate is 0% for both costs and effects | − €7957 | 0.23 | Dominant |
Utility data is based on literature retrieved in a systematic literature review | − €6136 | 0.19 | Dominant |
Utility data is based solely on trial data | − €6136 | 0.17 | Dominant |
Utility data is based on retrieved from the literature that was validated by the Dutch National Healthcare Institute | − €6136 | 0.19 | Dominant |
Patients are 45 years old at baseline | − €26,622 | 0.36 | Dominant |
Patients are 55 years old at baseline | − €17,733 | 0.29 | Dominant |
Patients are 65.8 years old at baseline (i.e., the average age of Dutch patients with T2D at CKD diagnosis) | − €5708 | 0.19 | Dominant |
The discount rate is 5% for both costs and effects | − €5766 | 0.14 | Dominant |
Time horizon 10 years | − €5396 | 0.11 | Dominant |
Solely direct dialysis costs are incorporated | − €4414 | 0.20 | Dominant |
Productivity losses are based on different sources | − €5545 | 0.20 | Dominant |